Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb randomized open-label study of GSK meningococcal ACWY conjugate vaccine versus Mencevax ACWY in healthy participants aged 11 to 55 years
2012-002722-75Phase 2
- Sponsor
- GSK
- Start
- May 2015
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of meningococcal conjugate vaccine GSK 134612 and meningococcal ACYW135 vaccine in meningococcal disease (2 arms), sponsored by GSK. Primary endpoint: Vaccine response to meningococcal antigens.
02
Drugs
meningococcal conjugate vaccine GSK 134612meningococcal ACYW135 vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2012-002722-75.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002722-75.